103 related articles for article (PubMed ID: 20678176)
1. Human immunodeficiency virus type 1 fitness and tropism: concept, quantification, and clinical relevance.
Clementi M; Lazzarin A
Clin Microbiol Infect; 2010 Oct; 16(10):1532-8. PubMed ID: 20678176
[TBL] [Abstract][Full Text] [Related]
2. Can modulation of viral fitness represent a target for anti-HIV-1 strategies?
Clementi M
New Microbiol; 2004 Jul; 27(3):207-14. PubMed ID: 15460522
[TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
4. Perspectives and opportunities for novel antiviral treatments targeting virus fitness.
Clementi M
Clin Microbiol Infect; 2008 Jul; 14(7):629-31. PubMed ID: 18190573
[TBL] [Abstract][Full Text] [Related]
5. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
6. Intra-host evolution of human immunodeficiency virus type 1 and viral fitness.
Clementi M; Canducci F; Bagnarelli P; Menzo S
New Microbiol; 2004 Apr; 27(2 Suppl 1):41-4. PubMed ID: 15646063
[TBL] [Abstract][Full Text] [Related]
7. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
[TBL] [Abstract][Full Text] [Related]
8. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
Martinez-Picado J; Martínez MA
Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
[TBL] [Abstract][Full Text] [Related]
10. Viral phenotype and fitness.
Andreoni M
New Microbiol; 2004 Apr; 27(2 Suppl 1):71-6. PubMed ID: 15646067
[TBL] [Abstract][Full Text] [Related]
11. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
12. T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells.
Neumann T; Hagmann I; Lohrengel S; Heil ML; Derdeyn CA; Kräusslich HG; Dittmar MT
Virology; 2005 Mar; 333(2):251-62. PubMed ID: 15721359
[TBL] [Abstract][Full Text] [Related]
13. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
14. Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.
McNicholas P; Vilchez RA; Greaves W; Kumar S; Onyebuchi C; Black T; Strizki JM
J Clin Virol; 2012 Oct; 55(2):134-9. PubMed ID: 22824230
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
16. Genotypic tropism of antiretroviral-treated patients with drug resistant HIV-1.
Parczewski M; Leszczyszyn-Pynka M; Urbanska A; Bander D; Boron-Kaczmarska A
J Med Virol; 2011 Nov; 83(11):1869-75. PubMed ID: 21915859
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
Bon I; Clò A; Borderi M; Colangeli V; Calza L; Morini S; Miserocchi A; Cricca M; Gibellini D; Re MC
Int J Infect Dis; 2013 Oct; 17(10):e875-82. PubMed ID: 23597487
[TBL] [Abstract][Full Text] [Related]
18. Methods to determine HIV-1 ex vivo fitness.
Abraha A; Troyer RM; Quiñones-Mateu ME; Arts EJ
Methods Mol Biol; 2005; 304():355-68. PubMed ID: 16061989
[TBL] [Abstract][Full Text] [Related]
19. Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.
Charpentier C; Joly V; Larrouy L; Fagard C; Visseaux B; de Verdière NC; Raffi F; Yeni P; Descamps D;
J Antimicrob Chemother; 2013 Mar; 68(3):690-6. PubMed ID: 23152480
[TBL] [Abstract][Full Text] [Related]
20. Tropism switch in patients infected with HIV-1 and its clinical implications for the treatment with CCR5-receptor inhibitors.
Arastéh K; Stocker H
Eur J Med Res; 2007 Oct; 12(9):397-402. PubMed ID: 17933720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
